Core Insights - Oruka Therapeutics has received mixed ratings from analysts, with Guggenheim initiating coverage with a "buy" rating and a target price of $60.00, while HC Wainwright lowered their target from $45.00 to $40.00, maintaining a "buy" rating [1] - The average target price for Oruka Therapeutics is $48.88, with one analyst rating it as a Strong Buy, seven as Buy, and one as Sell [1] - The company's stock has shown a recent increase of 4.1%, with a market cap of $1.47 billion and a P/E ratio of -15.95 [2] Financial Performance - Oruka Therapeutics reported earnings per share of ($0.55) for the last quarter, slightly beating analysts' expectations of ($0.56) [3] - Analysts project an earnings per share of -$3.41 for the current fiscal year [3] Insider Activity - Insider Joana Goncalves sold 7,000 shares at an average price of $30.61, totaling $214,270, which represents an 82.18% decrease in her ownership [4] Institutional Holdings - Institutional investors have increased their stakes in Oruka Therapeutics, with Woodline Partners LP boosting its stake by 46.9% and Fairmount Funds Management LLC increasing its holdings by 9.9% [5] - Institutional investors and hedge funds collectively own 56.44% of the company's stock [5] Company Overview - Oruka Therapeutics is a clinical-stage biopharmaceutical company focused on developing peptide-based therapies for oncology, utilizing a proprietary stapled peptide platform [7] - The lead candidate, ONCT-01, is currently in Phase 1 clinical trials for advanced solid tumors, assessing safety and preliminary efficacy [7]
Oruka Therapeutics (NASDAQ:ORKA) Stock Price Up 4.3% – Time to Buy?